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Abstract: Dermatoﬁ  brosarcoma protuberans (DFSP) is a soft tissue tumor with tendency to 
recur locally and only rarely metastasizes to vital organs. Surgery with wide margins remains 
the standard treatment. DFSP is characterized by speciﬁ  c chromosomal abnormalities involving 
the platelet derived growth factor B locus (PDGFB). In the majority of cases a supernumer-
ary ring chromosome containing ampliﬁ  ed t(17; 22) translocation or a linear unbalanced t(17; 
22) containing the COL1A1 –PDGFB fusion gene is present. This molecular event causes 
aberrant expression of a functional PDGFB leading to activation of PDGFR. Imatinib mesyl-
ate is a tyrosine kinase inhibitor with activity against activated PDGFR, and has signiﬁ  cant 
activity against DFSP. Clinical evidence suggests that it has a role in locally advanced and 
metastatic disease and clinical trials are ongoing examining its role in this rare but potentially 
fatal sarcoma.
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Introduction
Dermatoﬁ  brosarcoma protuberans (DFSP) is a rather uncommon soft tissue tumor of 
mesenchymal origin arising in the dermis. It is regarded as having intermediate malig-
nant potential between that of dermatoﬁ  broma (common ﬁ  brous histiocytoma) and 
malignant ﬁ  brous histiocytoma (MFH) (Weiss2001). It is one of several malignancies 
with deﬁ  ned aberrant molecular pathways that appear to be necessary for the sustained 
growth of neoplastic cells. The majority of DFSPs harbor at the cytogenetic level a 
rearrangement of chromosomes 17 and 22, manifested by the translocation t(17; 22) 
(q22; q13) or by a supernumerary ring chromosome containing several copies of the 
t(17:22) breakpoint region. These chromosomal abnormalities involve the platelet-
derived growth factor B locus (PDGF-B) and render DFSPs responsive to targeted 
therapy with the tyrosine kinase inhibitor imatinib mesylate (McArthur 2004, 2006; 
Abrams 2006). The aim of this review is to examine recent evidence regarding treat-
ment of DFSP with imatinib mesylate and other targeted therapies.
Clinical and pathologic features
DFSP accounts for less than 2% of all soft-tissue sarcomas (less than 0.1% of all can-
cers). It presents in all ages, including children, but the median age of patients with 
DFSP is 39–45 years. According to a review of 264 cases (Rutgers 1992) there is a 
slight male predominance (57% males, 43% females). Thus, it has a similar pattern of 
incidence as other mesenchymal sarcomas who present more commonly in the same 
age group. Most common location is the trunk (50%) but it can present in the proximal 
extremities (30%) and head and neck (10%–15%) (Laskin 1992). There are rare cases 
involving the hands and feet. Some locations like the head and neck pose unique prob-
lems since complete surgical removal can be disﬁ  guring. The usual presentation is an 
asymptomatic indurated plaque that may be red, brown, violaceous, or ﬂ  esh colored. Biologics: Targets & Therapy 2007:1(4) 348
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This plaque can be misdiagnosed for several years but it 
ﬁ  nally progresses to a ﬁ  rm raised and protuberant nodule 
that is ﬁ  xed to the skin but not to deeper tissues. Sometimes 
it can present as a sclerotic or soft, depressed plaque.
The rarity and variability in presentation of this disease 
leads to delayed or incorrect diagnosis. DFSP lesion size can 
range from 1 to 5 cm, although some reports describe lesions 
up to 40 cm. Ulceration and local bleeding have been reported 
too. Telangiectasias can be present at the overlying skin and, 
if left untreated, DFSP may inﬁ  ltrate fascia, muscle and even 
bone. During this phase, patients may report local pain.
Histological evaluations show a dense array of spindle-
shaped tumor cells with slender nuclei, intercellular collagen 
deposition, and small capillary blood vessels throughout. 
Tumors show a storiform or cartwheel pattern and polymor-
phism (Weiss 2001). Median mitotic rate is low usually less 
than four mitoses per 10 high-power ﬁ  elds. At the periphery 
of lesions, malignant cells mix into the dermal ﬁ  broblast 
matrix. The majority of DFSPs are CD34 positive by immu-
nostaining. This is of great assistance to the pathologist since 
this is a valuable but non-speciﬁ  c marker for the diagnosis. 
Most of the time, this CD34 positivity is diffuse but some 
cases show patchy pattern (Sirvent 2003). CD34 is expressed 
in hematopoetic progenitors including some leukemias, in 
endothelial cells and in some benign and malignant tumors. 
This feature of DFSP is hypothesis generating regarding its 
origin since recent studies support the existence of a common 
mesenchymal stem cell (Jiang 2002).
The diffuse pattern of inﬁ  ltration of subcutaneous tissues 
by DFSP may be the reason for the high propensity for local 
recurrence. Metastasis is quite unusual.
There are two important variants of DFSP. Pigmented 
DFSP, also known as Bednar’s tumor, displays a varying 
degree of melanin-containing dendritic cells interspersed in 
the tumor. Most authors believe that this variant does not have 
prognostic implication. On the other hand the ﬁ  brosarcoma-
tous variant of DFSP (FS-DFSP) is characterized by foci of 
high grade ﬁ  brosarcoma, in at least 5% of the total DFSP area. 
The ﬁ  brosarcoma variant has been found in reviews to have 
a great propensity of local recurrence (58%) and metastasis 
(15%). Due to these features FS-DFSPs require more extensive 
local treatment and closer follow up for possible development 
of metastases (McArthur 2004, 2006; Abrams 2006).
Cytogenetics and molecular 
features of DFSP
Cytogenetics analyses of DFSP have shown supernumerary 
ring chromosomes (Bridge 1990). Further research led to 
the discovery that this ring chromosome is derived from 
chromosome 22 and contain low level ampliﬁ  ed sequences 
from 17q22-qter and 22q10-13.1 or t(17; 22) usually unbal-
anced. This translocation results in the fusion of the COL1A1 
and PDGFB genes. The breakpoint on chromosome 17 
involves different regions of the COLI1A1 gene, from exon 
6 to exon 47 within the a-helical region, but the breakpoint 
on chromosome 22 always involves the first intron of 
PDGFB. In this way, PDGFB is placed under the control of 
the COL1A1 promoter that is more transcriptionally active 
than its own promoter. Processing this fusion gene leads to 
the formation of a functional PDGFB protein (O’Brien 1998; 
Shimizu 1999).
Thus, deregulated activation of PDGF-B is the critical 
molecular event in DFSP (see Figure 1). The linear translo-
cation is mostly found in pediatric cases (Pedeutour 1996; 
Sirvent 2003). This makes DFSP a neoplasm where the 
same molecular event, the COL1A1-PDGFB fusion, occurs 
on both supernumerary rings and linear chromosomes with 
an age-related pattern. There is no correlation between the 
breakpoint location on chromosome 17 and the age of the 
patient or the histological subtype (Sirvent 2003).
The DFSP molecular events can be examined using ﬂ  uo-
rescence in-situ hybridization (FISH ) or multiplex RT-PCR. 
For RT-PCR, a combination of various forward primers for 
COL1A1 and one reverse for PDGF-B need to be used. In 
Figure 2, cytogenetic analysis of our previously published 
case report is shown. The advantage of FISH is that it can be 
performed on parafﬁ  n-embedded tissue but it is challenging 
due to the unbalanced translocation characterizing DFSP.
In approximately 8% of DFSP the COL1A1-PDGFB 
fusion is not found suggesting that other genes may be 
involved in these cases, or that there is a cryptic rearrange-
ment of COL1A1 or PDGFB.
PDGFB acts as a ligand for both PDGFRα and PDGFRβ. 
In a seminal paper phosphorylation level of PDGFRβ was 
examined in ﬁ  ve DFSP tumor specimens by Western blot 
prior to treatment with imatinib. DFSP autocrine/paracrine 
PDGFRβ phosphorylation was at least 10-fold lower than the 
PDGFRα phosphorylation in a gastrointestinal stromal tumor 
sample (McArthur GA 2005). On the other hand, imatinib 
mesylate, a tyrosine kinase inhibitor of PDGFRs has clinical 
activity in DFSP, as will be discussed later. Thus, DFSP cells 
do not require high level of phosphorylation of PDGFRs and 
are ‘addicted’ to low levels of activation of receptor tyrosine 
kinases (Sirvent 2003).
Together with the speciﬁ  c ring and der(22) chromo-
somes associated with COL1A1 and PDGFB, additional Biologics: Targets & Therapy 2007:1(4) 349
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chromosomal abnormalities have been described in DFSP. 
The most common is trisomy 8, and less frequently trisomy 5 
(Sirvent 2003).
Standard treatment
The standard treatment of DFSP is wide surgical excision. 
Some authors suggest the use of Mohs’ micrographic sur-
gery where assessment of the margins is performed intra-
operatively. With this modality the amount of tissue excised 
can be minimized especially in visible areas. However, it is 
not available in many hospitals.
Excellent results have been published (Bowne 2000; 
Fiore 2005) using 2.5 cm margins but sometimes these 
wide margins lead to the need of reconstructive surgery. In 
the most recent study (Fiore 2005) from Milan, the outcome 
of patients with primary or recurrent DFSP was examined. 
This review included two hundred eighteen patients surgi-
cally treated at one institution over twenty years. In the 
136 patients with primary DFSP margins were positive in 
11.8% cases while in the 82 patients with recurrent disease 
margins were positive in 14.6% of cases. Reconstructive 
surgery was needed in 30% of all cases, more frequently in 
relapsed disease and in patients with head and neck loca-
tions. Long-term outcome was excellent with a local relapse 
rate of 4% and with a distant metastatic rate of 2% both at 
a median follow up of 10 years. In this study there were 
seven patients with FS-DFSP and two of them developed 
distant metastases and eventually died. In contrast, out of 
211 patients with classic DFSP, only 3 developed distant 
metastases, and two of them were progression free after 
excision of metastases.
The role of radiotherapy in DFSP is not extensively studied. 
Retrospective series have shown that radiotherapy is of beneﬁ  t 
in the management of margin positive disease and in cases 
where adequate wide excision would result in major cosmetic 








Figure 1 COL1A1-PDGFB fusion acts as a fully functional PDGFB activating PDGFR. Imatinib as a PDGFB receptor tyrosine kinase inhibitor blocks intracellular signal 
transduction.
Figure 2 Dual-color PDGFB FISH showing PDGFB rearrangement in most cells. 
Arrows indicate two cells in which a normal chromosome 22 (red-green paired 
signals) and an abnormal ring-chromosome (cluster of red signals) are seen.  The full 
complement of FISH signals is not seen due to the nuclear slicing effect in a four-
micron section, and because the image conveys a single plane of focus. Copyright © 
2005. Reprinted with permission from Labropoulos SV, Fletcher JA, Oliveira AM, et al. 
2005. Sustained complete remission of metastatic dermatoﬁ  brosarcoma protuberans 
with imatinib mesylate. Anticancer Drugs, 16:461–6.Biologics: Targets & Therapy 2007:1(4) 350
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or functional deﬁ  cits. Radiation doses of 50–60 Gy should be 
considered (Suit 1996; Ballo 1998). The good results obtained 
with imatinib in advanced cases suggest the need for a direct 
comparison of these two treatment modalities.
Targeted therapy
The fusion protein derived from the translocation of COL1A1-
PDGFB acts in the cells as fully functional PDGF-B. This 
functional PDGF-B-like protein form homodimers and, 
by an autocrine and paracrine loops, promote ligand driv-
ing proliferation through the two receptors PDGFRα and 
PDGFRβ. Since PDGFRβ is the major isoform expressed in 
DFSP, the t(17; 22) derived fusion protein most likely acts as 
this receptor’s ligand (see Figure 1). In vitro evidence sug-
gests that when this fusion protein was expressed in a stable 
NIH 3T3 cell line, it caused morphological transformation 
and increased growth of cells. Cells transformed with the 
COL1A1-PDGFB gene as well as cell cultures derived from 
patients with DFSP are inhibited by the tyrosine kinase inhibi-
tor imatinib mesylate (Glivec or STI-571; Novartis, Basel, 
Switzerland) (Greco 2001, Sjoblom 2001).
Several published reports indicate that imatinib has 
signiﬁ  cant activity against DFSP (Table 1). The ﬁ  rst experi-
ence was published in 2002 (Maki 2002 ). Two patients with 
metastatic DFSP were treated with imatinib at 400 mg/d after 
failure of chemotherapy. Available tissue showed that both 
had ﬁ  brosarcomatous DFSP and one of the two cases was 
karyotyped. The karyotype showed two ring chromosomes 
but there was no involvement of 22q13 where the PDGFB 
gene is located. This patient had a transient response during 
the ﬁ  rst month of treatment but then progressed and died 
of his disease. The second reported patient did not have a 
karyotype performed but had a very good partial response 
after 2 months of imatinib with resolution of superior vena 
cava syndrome and pulmonary metastases. This response 
was sustained at 6 months of treatment.
The same year in a different case report a patient with 
unresectable metastatic DFSP was treated with imatinib at 
400 mg twice daily (Rubin 2002). He had presented with 
a paraspinous mass, and after 2 weeks of treatment he had 
clinical improvement. FDG-PET showed normalization of 
glucose uptake. During 4 months of imatinib treatment the 
tumor shrank by 75%, allowing the resection of the mass. 
No viable tumor cells were seen in the resected specimen 
indicating a complete pathologic remission to imatinib 
mesylate. This pathologic ﬁ  nding is a proof of concept of the 
dichotomy between anatomic imaging studies and response 
to sarcoma treatment. This patient had a complex karyotype 
with a 22q13 translocation with an unidentiﬁ  ed partner. No 
ring chromosome and no t(17; 22) was identiﬁ  ed.
The largest study with imatinib in DFSP patients was 
reported in 2005 and involved both locally advanced and 
metastatic disease (McArthur 2005). This study was a 
multicenter phase II trial of imatinib at the dose of 400 mg 
twice daily and involved 10 patients. This high dose was 
well tolerated except in one patient who required reduc-
tion to 600 mg/d. This study is of interest since it included 
molecular, cytogenetic and kinase activation proﬁ  les in order 
to evaluate possible correlation of tumor proﬁ  le with response 
to imatinib. In four patients, biopsies were performed before 
and after 28 days of treatment. Eight patients had locally 
advanced disease and two achieved pathologic complete 
remission (CR) and two radiologic CR. The other four had 
partial responses and with subsequent surgical resection 
were rendered disease free. Follow up of these patients 
ranged from 88 to 845 days. Notably all patients with locally 
Table 1 Clinical experience with imatinib in DFSP
Patients  Histology  Stage  Dose mg/day   Response   Cytogenetics  Reference
2  DFSP-FS  Metastatic  400  One PR  Complex t(17; 22) present  Maki
       One  PD 
1  DFSP  Metastatic   800  Path CR  Complex t(17; 22) present  Rubin
1  DFSP-FS  Metastatic  400  CR  Present t(17; 22) by FISH  Labropulos
1 DFSP-FS  Metastatic  400  PR  COL1A1-PDGFB  by  FISH  Misutani
1  DFSP   Metastatic   400  PR  Not reported  Baars
1  DFSP  Metastatic  400  SD by RECIST  Not reported  Kaspar
        PR by PET   
2  DFSP-FS  Metastatic   800   One PR  Complex with t(17; 22)  McArthur
        One SD  Complex no t(17; 22) 
8  DFSP  Locally advanced  800  Two CR  t(17; 22)  McArthur
        Two path CR  t(17; 22) 
        Four PR Resection   t(17; 22) Biologics: Targets & Therapy 2007:1(4) 351
Imatinib, dermatoﬁ  brosarcoma protuberans
advanced disease had partial (50%) or complete remission to 
imatinib. All of these patients had a typical ring chromosome 
t(17; 22). Two patients had metastatic disease. One had a 
good partial response for 6 months on imatinib treatment 
but subsequently developed disease progression. The second 
patient with metastatic disease had no clinical response to 
imatinib and died of complications of a pathologic fracture 
21 days after starting imatinib. Both of these patients had 
complex karyotypes. The one who did not respond clinically 
did not harbor PDGF-B rearrangement by FISH in parafﬁ  n 
tumor sections or in cytogenetic preparations. The one who 
responded for 6 months had the t(17; 22) translocation with 
several copies of a ring chromosome. FISH for PDGF-B 
conﬁ  rmed the t(17; 22) in the ring chromosomes.
As described previously pretreatment phosphorylation 
levels of PDGFR-β were performed in DFSP samples and 
revealed low level of activity suggesting that the malignant 
phenotype of this disease does not require high level or 
upregulation of kinase activity. Thus inhibition of low-level 
receptor tyrosine kinase activity is effective since the tumor 
cells are addicted to this signaling mechanism. This is in 
contrast with ﬁ  ndings of high-level receptor tyrosine kinase 
activity of PDGF-Α in GIST tumors.
In several patients matched pretreatment and on-therapy 
tumor biopsy specimens were obtained. During imatinib 
treatment the specimens had reduced cellularity and hyaline 
changes. PDGFB by FISH showed persistence of the t(17; 22) 
translocation in the spindle-cell component of the disease. 
Of interest the translocation was found in only 20% of these 
spindle cells suggesting that most of them were either reac-
tive or cells lacking the t(17; 22) translocation (McArthur 
GA 2005).
In our case report (Labropoulos 2005), a patient with 
locally recurrent and metastatic to the lungs ﬁ  brosarcomatous 
DFSP was treated with imatinib at 400 mg/d.This patient was 
resistant to previous anthracycline chemotherapy and had 
both soft tissue and lung metastases. Within the ﬁ  rst month 
of treatment clinical response was observed at the local site 
and subsequent FDG-PET and CT demonstrated complete 
radiologic response. The lung lesions were not FDG avid, 
but this was thought to be explained by their size (maximal 
diameter 8mm), which was below the resolution of the PET 
scanner. However, by CT scans these lesions disappeared 
during treatment with imatinib. FISH study of the tumor with 
novel probes demonstrated PDGFB rearrangement in most 
cells (Figure 2).This patient remained in CR on imatinib 
400 mg/d for over 2 years and had only mild hematologic 
toxicity (anemia), and peripheral edema which did not require 
interruption of imatinib. Almost at two years on this treatment 
she developed recurrence both in soft tissues and lungs. Her 
dose of imatinib was increased to 400 mg twice a day with 
no response and underwent resection of lung metastases. Sub-
sequently she progressed and is now on second line targeted 
therapy with the tyrosine kinase inhibitor sunitinb which has 
activity in imatinib resistant GIST. So far she seems to be 
responding in soft tissue and pleural based disease with no 
severe toxicity (unpublished).
In a pediatric case with a large extremity DFSP, response 
to imatinib was documented by MRI after 23 weeks of 
neoadjuvant therapy. The dose was 400 mg/m2 once a day 
and was further increased to 520 mg/m2/day. FISH study 
of the tumor showed PDGF-B rearrangement. This is the 
ﬁ  rst report of a pediatric DFSP who exhibited response to 
imatinib. This 18 month old girl had a large lower extremity 
DFSP (initially assumed to be a hemangioma). Immediate 
surgical resection would have caused unacceptable functional 
defects (Price 2005).
Another case report (Kaspar 2006) described a patient 
with locally recurrent and metastatic DFSP who had under-
gone surgery 22 times. The patient had a large mesenteric 
mass with retroperitoneal lymph nodes. He was initially 
treated at 400 mg/d, which was increased to 400 mg twice 
a day. Clinical response was seen after the ﬁ  st month of 
therapy. Metabolic response was documented by FDG-PET 
both at one month and at 12 weeks on treatment. However 
by CT the patient had a minor decrease of the mass size 
classiﬁ  ed as stable disease by response evaluation criteria in 
solid tumors (RECIST). No cytogenetic or RT-PCR data were 
reported. The use of classical RECIST criteria in imatinib 
treated GISTs may lead to erroneous conclusions regarding 
tumor responsiveness. As reported recently in GISTs, a 10% 
decrease in size or a 15% decrease in density on contrast 
enhanced CT correlated well with response by PET measure-
ments and was more predictive of time to tumor progression 
than response by RECIST (Benjamin 2007).
Another partial response of a metastatic DFSP with ima-
tinib was described in a case report from the Netherlands but 
further details were unavailable (Baars 2003).
Finally a patient with metastatic DFSP to the lungs had a 
partial response to imatinib 400 mg/d. FISH demonstrated 
the COL1A1-PDGF-B translocation. This case is presented 
in a letter form (Mizutani 2004).
In all these reported cases imatinib was well tolerated in the 
dose range of 400 to 800 mg per day. Experience from larger 
studies in GIST tumors suggests that the higher dose is more 
often associated with side effects requiring dose reduction.Biologics: Targets & Therapy 2007:1(4) 352
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Many questions arise from these reports of imatinib 
activity in this soft tissue sarcoma (Abrams 2006, McArthur 
2005). First, does response to imatinib correlate with 
the cytogenetic ﬁ  ndings or histologic features? The ﬁ  rst 
impression is that patients who respond have evidence of 
PDGF-B rearrangement Complex cytogenetics and/or no 
PDGF-B rearrangement may be negative predictive factors 
for response to imatinib. Some authors have suggested that 
histologic features of DFSP such as a ﬁ  brosarcomatous 
component may render these tumors less responsive but other 
reports and our own experience have shown good response 
in ﬁ  brosarcomatous DFSPs.
Another important question is the dose. The dose of ima-
tinib varies from 400 mg/d to 400 mg twice a day and at this 
point there is no evidence that there is a dose effect on this 
disease. One could suggest starting at lower dose and if there 
is no response increasing the dose to 400 mg twice a day.
The use of RECIST criteria has been questioned in ima-
tinib treated GISTs. In some of the case reports regarding 
imatinib treated DFSPs response was earlier and sometimes 
only evaluable by FDG-PET raising similar questions to 
the ones discussed in GISTs (Benjamin 2007). Duration of 
treatment is another factor and so far, the clinical practice is 
to continue treatment until disease progression based on the 
experience with GISTs.
Further important questions include the clinical use of 
imatinib as neoadjuvant therapy especially in large tumors 
requiring extensive and potentially disﬁ  guring surgery and 
the use of imatinib as adjuvant treatment after surgical resec-
tion in cases with large tumors or DFSPs with aggressive 
histologic features. The latter is particularly interesting in 
view of new evidence that adjuvant imatinib is of beneﬁ  t 
to patients with surgically resected large and histologically 
aggressive GISTs.
Over the last few years many novel targeted agents with 
tyrosine kinase inhibitor action have become available in the 
clinic. Some of these agents have activity against PDGFB 
and some act in multiple pathways including angiogenesis. 
Two of these agents, sunitinib and sorafenib, are active and 
approved for patients with metastatic renal cancer, while 
sunitinib is active in imatinib resistant or progressing GISTs. 
It will be of great interest to test these drugs in the laboratory 
against DFSP cell lines to obtain solid evidence of potential 
activity. In the clinic they could be tried in patients who 
are refractory or progressing on imatinib and who have 
no other therapeutic option. Patients who progress on one 
targeted agent seem to harbor mutations that render them 
sensitive to a second line targeted agent. Evidence for this 
is accumulating from the treatment of chronic myelogenous 
leukemia (Kantarjian H 2006; Talpaz 2006).
Clinical trials
Despite the evidence from the above studies imatinib is 
not yet approved by the American or European regulatory 
authorities for use in DFSP. Being rare and usually curable by 
surgery DFSP is a very difﬁ  cult disease to perform large-scale 
randomized trials in this disease. At this juncture there are 
three very important multicenter phase II studies attempting 
to answer questions regarding the use of imatinib in locally 
advanced and metastatic DFSP (Abrams 2006).
One study from North America sponsored by National 
Cancer Institute and by Southwest Oncology Group (SWOG) 
addresses the issue of using imatinib in patients where local 
resection of DFSP would have an unacceptable cosmetic 
result or impairment. Patients are allowed to enter irrespec-
tive of having the COL1A1-PDGFB fusion gene but PDGFB 
studies will be performed on the tumor specimens. Starting 
dose is 400 mg/d and the dose can be escalated to 400 mg 
twice a day if there is tumor progression and signiﬁ  cant 
toxicity is absent.
The second study is sponsored by the European Orga-
nization for Reasearch and Treatment (EORTC) excludes 
patients who could be cured by local surgery. Additionally in 
this study the presence of COL1A1-PDGF-B fusion gene is 
required. The dose of imatinib is at 400 mg twice a day. The 
pre-entry criterion of the fusion gene may miss the oppor-
tunity to see imatinib activity in patients where neoplasia is 
driven by alternate partners of PDGF-B.
Both studies aim at accruing 40 patients if activity of 
imatinib is seen but differ in their endpoints. The American 
study is examining response rate and the European progres-
sion free survival at 14 weeks on treatment.
A third phase II study is activated by the Sarcoma Alli-
ance for Research, and is attempting to look at the molecular 
activity of imatinib in primary DFSP. Before deﬁ  nitive surgi-
cal treatment patients will receive imatinib at 400 mg twice 
daily for 10 to 14 days. Resected tumor will be studied for 
molecular effects of imatinib on PDGFR and downstream 
molecules.
In view of the rarity of this disease and the many questions 
regarding evidence based use of imatinib, patients and their phy-
sicians are strongly encouraged to participate in these studies.
Conclusions
DFSP is a rare soft tissue sarcoma that can be cured by 
appropriate surgery in the majority of cases. It has a unique Biologics: Targets & Therapy 2007:1(4) 353
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molecular characteristic involving the PDGF-B locus with the 
presence of ring chromosomes containing several copies of 
the t(17; 22) translocation or a linear t(17; 22). In challenging, 
locally advanced disease and in the rare metastatic cases 
imatinib mesylate has shown impressive single agent activ-
ity with limited toxicity. Several basic science and clinical 
questions need to be answered by collaborative approach 
while other novel tyrosine kinase inhibitors need to be tested 
in imatinib refractory or progressing cases. The knowledge 
of basic molecular pathways has led to this new therapy for 
patients with DFSP, and is an example of the potential beneﬁ  t 
of translational research in solid tumors.
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